Vena cava replacement and major hepatectomy for liver tumors: international multicenter retrospective cohort study.


Journal

International journal of surgery (London, England)
ISSN: 1743-9159
Titre abrégé: Int J Surg
Pays: United States
ID NLM: 101228232

Informations de publication

Date de publication:
11 Apr 2024
Historique:
received: 22 12 2023
accepted: 11 03 2024
medline: 12 4 2024
pubmed: 12 4 2024
entrez: 12 4 2024
Statut: aheadofprint

Résumé

Involvement of the inferior vena cava (IVC) and hepatic veins (HV) has been considered a relative contraindication to hepatic resection for primary and metastatic liver tumors. However, patients affected by tumors extending to the IVC have limited therapeutic options and suffer worsening of quality of life due to IVC compression. Cases of primary and metastatic liver tumors with vena cava infiltration from 10 international centers were collected (7 European, 1 US, 2 Brazilian, 1 Indian) were collected. Inclusion criteria for the study were major liver resection with concomitant vena cava replacement. Clinical data and short-term outcomes were analyzed. 36 cases were finally included in the study. Median tumor max size was 98 mm (range: 25-250). A biliary reconstruction was necessary in 28% of cases, while a vascular reconstruction other than vena cava in 34% of cases. Median operative time was 462 min (range: 230-750), with 750 median ml of estimated blood loss and a median of one pRBC transfused intraoperatively (range: 0-27). Median ICU stay was 4 days (range: 1-30) with overall in-hospital stay of 15 days (range: 3-46), post-operative CCI score of 20.9 (range: 0-100), 12% incidence of PHLF grade B-C. Five patients died in a 90-days interval from surgery, 1 due to heart failure, 1 due to septic shock and 3 due to multiorgan failure. With a median follow-up of 17 months (interquartile range: 11-37), the estimated five-years overall survival was 48% (95% CI: 27%-66%), and five-year cumulative incidence of tumor recurrence was 55% (95% CI: 33%-73%). Major liver resections with vena cava replacement can be performed with satisfactory results in expert HPB centers. This surgical strategy represents a feasible alternative for otherwise unresectable lesions and is associated with favorable prognosis compared to non-operative management, especially in patients affected by intrahepatic cholangiocarcinoma.

Identifiants

pubmed: 38608195
doi: 10.1097/JS9.0000000000001386
pii: 01279778-990000000-01335
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.

Auteurs

Fabrizio Di Benedetto (F)

Hepato-pancreato-biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, Italy.

Paolo Magistri (P)

Hepato-pancreato-biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, Italy.

Francesca Marcon (F)

HPB Surgery and Liver Transplant, Queen Elizabeth Hospital, Birmingham, UK.

Olivier Soubrane (O)

Department of HPB and Liver Transplantation, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris and Université de Paris, Clichy, France.

Felipe Pedreira Mello (F)

Department of Surgery and abdominal organ transplantation - Hospital Adventista Silvestre, Rio de Janeiro, Brazil.

Joao Santos Coelho (J)

Hepato-Biliary-Pancreatic and Transplantation Center, Department of Surgery, Curry Cabral Hospital, Lisbon, Portugal.

Andre Renaldo Fernandez (AR)

Division of Transplantation and Hepatobiliary Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA.

Samuele Frassoni (S)

Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.

Vincenzo Bagnardi (V)

Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.

Ashish Singhal (A)

Advanced Institute of Liver & Biliary Sciences, Fortis Hospitals, Delhi, NCR, India.

Fernando Rotellar (F)

HPB and Liver Transplantation Unit, Department of Surgery, University Clinic, Universidad de Navarra; Institute of Health Research of Navarra (IdisNA), Pamplona, Spain.

Roberto Hernandez-Alejandro (R)

Division of Transplantation and Hepatobiliary Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA.

Ruslan Alikhanov (R)

Department of Hepato-Pancreato-Biliary Surgery and Department of Transplantation, Moscow Clinical Scientific Center, Moscow, Russia.

Eduardo de Souza M Fernandes (E)

Department of Surgery and abdominal organ transplantation - Hospital Adventista Silvestre, Rio de Janeiro, Brazil.
Hepato-pancreato-biliary Unit and Transplant - DHR Health, McAllen, Texas, USA.

Francois Cauchy (F)

Department of HPB and Liver Transplantation, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris and Université de Paris, Clichy, France.

Paolo Muiesan (P)

HPB Surgery and Liver Transplant, Queen Elizabeth Hospital, Birmingham, UK.

Stefano Di Sandro (S)

Hepato-pancreato-biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, Italy.

Hugo Pinto Marques (H)

Hepato-Biliary-Pancreatic and Transplantation Center, Department of Surgery, Curry Cabral Hospital, Lisbon, Portugal.

Classifications MeSH